Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Establishing System Suitability Criteria – V 2.0

Posted on By

Analytical Method Development: SOP for Establishing System Suitability Criteria – V 2.0

Standard Operating Procedure for Establishing System Suitability Criteria in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/362/2025
Supersedes SOP/AMD/362/2022
Page No. Page 1 of 14
Issue Date 01/06/2025
Effective Date 04/06/2025
Review Date 01/06/2027

1. Purpose

The purpose of this SOP is to provide a structured procedure for establishing, evaluating, and documenting system suitability criteria in analytical methods developed for qualitative and quantitative analysis of pharmaceutical substances and products.

2.

Scope

This SOP applies to all analytical methods developed and validated within the Analytical Method Development (AMD) department, including chromatographic (HPLC/GC), spectrophotometric (UV), and titrimetric methods where system performance indicators must be defined.

3. Responsibilities

  • Analytical Scientist: Designs the method, executes experiments, and proposes system suitability parameters.
  • QA Reviewer: Verifies adequacy and relevance of the established criteria in line with regulatory standards.
  • Department Head: Approves final system suitability specifications to be included in method validation reports.

4. Accountability

The AMD Department Head is accountable for ensuring compliance of system suitability parameters with current Good Manufacturing Practice (cGMP) guidelines and ICH Q2(R1) expectations.

5. Procedure

5.1 Understanding System Suitability

System suitability tests are integral to analytical methods and ensure that the complete system (instrument, column, reagents, analyst) is performing adequately before analysis of test samples. Parameters include but are not limited to resolution, tailing factor, theoretical plates, repeatability (RSD), and signal-to-noise ratio.

5.2 Selection of System Suitability Parameters

  1. Identify critical quality attributes (CQA) of the analyte (e.g., retention time, peak shape, resolution from adjacent peaks).
  2. During method development, inject a system suitability solution containing the analyte(s) and related substances.
  3. Measure:
    • Resolution (Rs): Between analyte and nearest impurity.
    • Tailing Factor (T): Should be ≤ 2.0 unless otherwise justified.
    • Theoretical Plates (N): Minimum acceptance values as per method design.
    • RSD (%): Peak area from replicate injections (typically 5 or 6).

5.3 Repeatability and Reproducibility

  1. Inject 5–6 replicate injections of standard solution at the beginning of each analytical run.
  2. Calculate RSD of peak area or peak height.
  3. Acceptable RSD: ≤ 2.0% unless specific product guidance or ICH justification exists.

5.4 Documentation of Parameters

  1. Document parameter values observed during method optimization (Annexure-1).
  2. Justify each selected parameter based on regulatory precedence or historical performance.
  3. Ensure parameters are included in the method validation protocol and report.

5.5 Revalidation or Updates

  1. Re-evaluate system suitability if there are changes to:
    • Column type or dimension
    • Instrument make/model
    • Mobile phase pH or composition
  2. Document changes and justification for any revised criteria in Annexure-2.

5.6 Failure of System Suitability

  1. If system suitability criteria fail:
    • Do not inject samples.
    • Document failure in Analytical Logbook (Annexure-3).
    • Investigate and correct root cause before proceeding.

6. Abbreviations

  • Rs: Resolution
  • RSD: Relative Standard Deviation
  • cGMP: Current Good Manufacturing Practices
  • ICH: International Council for Harmonisation
  • HPLC: High Performance Liquid Chromatography

7. Documents

  1. Annexure-1: System Suitability Design Log
  2. Annexure-2: Revalidation Criteria Update Sheet
  3. Annexure-3: System Suitability Failure Log

8. References

  • ICH Q2(R1) – Validation of Analytical Procedures
  • USP General Chapter <621> – Chromatography
  • FDA Guidance – Analytical Procedures and Methods Validation

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Anjali Thakur Yogesh More Dr. Ashwini Shah
Designation Senior Analyst – AMD QA Executive Department Head
Department Analytical Method Development Quality Assurance Analytical Method Development

11. Annexures

Annexure-1: System Suitability Design Log

Method ID Analyte System Parameter Target Value Rationale
AMD-MTH-362-01 API-A Rs ≥ 2.0 2.3 Critical separation from impurity B
AMD-MTH-362-01 API-A Tailing Factor ≤ 1.5 Peak symmetry

Annexure-2: Revalidation Criteria Update Sheet

Date Change Reason Impact Updated By
12/04/2025 Column change: C18 to Phenyl Improved selectivity Updated Rs and TF criteria Anjali Thakur

Annexure-3: System Suitability Failure Log

Date Instrument ID Failure Description Action Taken Status
21/05/2025 HPLC-012 RSD > 2.5% Column flushed, standard re-prepared Resolved

Revision History:

Revision Date Revision No. Details Reason Approved By
01/06/2025 2.0 Inclusion of Annexure-3 and root cause tracking format Annual SOP Review Dr. Ashwini Shah
12/09/2022 1.0 Initial issue New Method SOP QA Head
See also  Analytical Method Development: SOP for Plume Geometry Analysis Method Development - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Analytical Method Development: SOP for Performing Precision Studies in Method Validation – V 2.0
Next Post: Analytical Method Development: SOP for Selection of Analytical Techniques – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version